FDG PET/CT is being combined with clinical and pathology variables to refine relapse risk in MALT lymphoma. Researchers in Wuhan developed a prognostic nomogram that integrates imaging metabolism with other disease factors to predict progression-free survival and improves risk stratification inside intermediate-risk patients. The update highlights a practical direction for oncology decision-making: using standardized PET parameters alongside traditional staging inputs to reduce uncertainty after treatment. For clinicians and product teams, the central point is the attempt to convert PET signal into a usable bedside model rather than treating PET metrics as standalone descriptors.